keyword
MENU ▼
Read by QxMD icon Read
search

american society of clinical oncology

keyword
https://www.readbyqxmd.com/read/28340220/her2-neu-status-determination-in-breast-cancer-a-single-institutional-experience-using-a-dual-testing-approach-with-immunohistochemistry-and-fluorescence-in-situ-hybridization
#1
James P Solomon, Marie Dell'Aquila, Oluwole Fadare, Farnaz Hasteh
Objectives: According to current guidelines, either immunohistochemistry (IHC) or in situ hybridization (ISH) can be used to determine human epidermal growth factor receptor 2 (Her2/neu) status in breast carcinoma. While the guidelines explicitly delineate result interpretation, there is no consensus on the most appropriate testing algorithm. Methods: The Her2/neu statuses of 369 consecutive cases of invasive breast cancer (from 351 patients) were assessed in a dual-testing algorithm that uses both IHC and fluorescence ISH (FISH)...
March 11, 2017: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28334713/pulsed-dose-rate-brachytherapy-for-the-treatment-of-endometrial-cancer
#2
Francesca De Felice, Rossella Caiazzo, Ilaria Benevento, Daniela Musio, Filippo Rubini, Vincenzo Tombolini
Endometrial cancer (EC) is the most frequent gynecologic malignancy. The aim of this review is to outline clinical practice recommendations, to suggest a technical solution, and to advise doses selection for pulsed-dose rate (PDR) brachytherapy in EC. Electronic bibliographic databases, including PubMed, clinicaltrials.gov, and the American Society of Clinical Oncology (ASCO) Meeting Library, were searched for articles in English. Clinical guidelines and systematic reviews were also considered. The appropriate therapeutic approach should consider risk factors for tumor relapse and PDR brachytherapy and have a convincing role in this multidisciplinary scenario...
March 24, 2017: Oncology
https://www.readbyqxmd.com/read/28326862/the-state-of-cancer-care-in-america-2017-a-report-by-the-american-society-of-clinical-oncology
#3
(no author information available yet)
No abstract text is available yet for this article.
March 22, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28322840/med1-mayexplainthe-interaction-between-receptortyrosinekinasesand-er%C3%AE-66-in-the-complicated-network-of-tamoxifen-resistant
#4
REVIEW
Sepideh Mansouri, Fatemeh Naghavi-Al-Hoseini, Leila Farahmand, Keivan Majidzadeh-A
According to the American Society of Clinical Oncology or ASCO's clinical practice guidelines, administration of Tamoxifen for hormone receptor positive patients improved outcomes. However, many studies have been conducted in this issue, with the rise of Tamoxifen resistance in recent decades. There are many alternative growth cascades that are activated in Tamoxifen resistant cells. The most common and well characterized components of such a resistant network are receptor tyrosine kinases, or RTKs, which can influence many othercellular processes...
March 16, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28319263/a-review-of-family-caregiving-intervention-trials-in-oncology
#5
REVIEW
Betty Ferrell, Elaine Wittenberg
This article contains a review of literature published from 2010 to 2016 on family caregiving in oncology. An analysis of 810 citations resulted in 50 randomized trials. These trials describe the need to prepare family caregivers for the complex role they play in cancer care. Several studies have demonstrated improved quality of life for family caregivers and improved emotional support from interventions. Several studies addressed communication and relational intimacy, which are key concerns. An additional focus of these trials was in the area of caregiving tasks and ways to diminish the burden of caregiving and preparedness for this role...
March 20, 2017: CA: a Cancer Journal for Clinicians
https://www.readbyqxmd.com/read/28303435/systemic-combination-chemotherapy-in-elderly-pancreatic-cancer-a-review
#6
REVIEW
Gwenalyn Garcia, Marcel Odaimi
PURPOSE: In recent years, significant progress in survival has been achieved using systemic combination chemotherapy in patients with pancreatic cancer. However, the elderly are largely underrepresented in clinical trials, and gains made from these may not necessarily apply to this important subgroup of patients. We review the currently available data regarding contemporary combination chemotherapy regimens, including FOLFIRINOX, gemcitabine plus nab-paclitaxel, nanoliposomal irinotecan plus 5-fluorouracil and leucovorin, and gemcitabine plus capecitabine, in elderly pancreatic cancer patients...
March 16, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28301279/integrating-palliative-care-services-in-ambulatory-oncology-an-application-of-the-edmonton-symptom-assessment-system
#7
Sherri L Rauenzahn, Susanne Schmidt, Ifeoma O Aduba, Jessica T Jones, Nazneen Ali, Laura L Tenner
PURPOSE: Research in palliative care demonstrates improvements in overall survival, quality of life, symptom management, and reductions in the cost of care. Despite the American Society of Clinical Oncology recommendation for early concurrent palliative care in patients with advanced cancer and high symptom burden, integrating palliative services is challenging. Our aims were to quantitatively describe the palliative referral rates and symptom burden in a South Texas cancer center and establish a palliative referral system by implementing the Edmonton Symptom Assessment Scale (ESAS)...
March 16, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28282999/critical-decision-making-in-radiotherapy-for-early-stage-breast-cancer-in-a-neo-adjuvant-treatment-era
#8
Francesca De Felice, Mattia Falchetto Osti, Vitaliana De Sanctis, Daniela Musio, Vincenzo Tombolini
Introduction In breast cancer management, the role of adjuvant radiation therapy (RT) has been the subject of intense controversy over the past several years, due to the improvement in neoadjuvant chemotherapy (NACT) prescription. One of the most controversial questions regarding indication for adjuvant RT is whether or not RT is essential in patients with early stage disease at diagnosis. The value of adjuvant RT remains highly debatable in those patients with clinically negative nodes at the completion of NACT...
March 10, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28282276/american-society-of-clinical-oncology-criteria-for-high-quality-clinical-pathways-in-oncology
#9
Robin T Zon, Stephen B Edge, Ray D Page, James N Frame, Gary H Lyman, James L Omel, Dana S Wollins, Sybil R Green, Linda D Bosserman
No abstract text is available yet for this article.
March 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28275115/safety-and-tolerability-of-pd-1-pd-l1-inhibitors-compared-with-chemotherapy-in-patients-with-advanced-cancer-a-meta-analysis
#10
Tomohiro F Nishijima, Shlomit S Shachar, Kirsten A Nyrop, Hyman B Muss
BACKGROUND: Compared with chemotherapy, significant improvement in survival outcomes with the programmed death receptor-1 (PD-1) inhibitors nivolumab and pembrolizumab and the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab has been shown in several types of advanced solid tumors. We conducted a systematic review and meta-analysis to compare safety and tolerability between PD-1/PD-L1 inhibitors and chemotherapy. METHODS: PubMed and American Society of Clinical Oncology (ASCO) databases were searched 1966 to September 2016...
March 8, 2017: Oncologist
https://www.readbyqxmd.com/read/28274395/attitudes-of-radiation-oncologists-toward-palliative-and-supportive-care-in-the-united-states-report-on-national-membership-survey-by-the-american-society-for-radiation-oncology-astro
#11
Randy L Wei, Malcolm D Mattes, James Yu, Adrienne Thrasher, Hui-Kuo Shu, Harald Paganetti, Jennifer De Los Santos, Bridget Koontz, Christopher Abraham, Tracy Balboni
PURPOSE: Radiation oncologists are frequently involved in providing palliative and supportive care (PSC) for patients with advanced cancers through delivery of palliative radiation. Whether they are confident in their ability to assess and initiate treatments for pain, nonpain, and psychosocial distress is unknown. The American Society for Radiation Oncology surveyed its practicing members in the United States on self-assessment of their primary PSC skills and access to continuing medical education on PSC...
March 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28272845/accuracy-of-next-generation-sequencing-for-the-identification-of-clinically-relevant-variants-in-cytology-smears-in-lung-adenocarcinoma
#12
Jordan E Baum, Pan Zhang, Rana S Hoda, Brian Geraghty, Hanna Rennert, Navneet Narula, Helen D Fernandes
BACKGROUND: Minimally invasive diagnostic procedures such as needle-core biopsy and fine-needle aspiration provide adequate material for molecular analyses. Advances in precision oncology are trending toward the interrogation of limited amounts of genomic material to guide clinical and therapeutic decisions. The aim of this study was to investigate the minimum cellularity needed on cytologic smears for the identification of clinically relevant variants with next-generation sequencing (NGS)...
March 8, 2017: Cancer
https://www.readbyqxmd.com/read/28266033/first-international-consensus-report-on-adnexal-masses-management-recommendations
#13
Phyllis Glanc, Beryl Benacerraf, Tom Bourne, Douglas Brown, Beverly G Coleman, Christopher Crum, Jason Dodge, Deborah Levine, Edward Pavlik, Dirk Timmerman, Frederick R Ueland, Wendy Wolfman, Steven R Goldstein
The First International Consensus Conference on Adnexal Masses was convened to thoroughly examine the state of the science and to formulate recommendations for clinical assessment and management. The panel included representatives of societies in the fields of gynecology, gynecologic oncology, radiology, and pathology and clinicians from Europe, Canada, and the United States. In the United States, there are approximately 9.1 surgeries per malignancy compared to the European International Ovarian Tumor Analysis center trials, with only 2...
March 7, 2017: Journal of Ultrasound in Medicine: Official Journal of the American Institute of Ultrasound in Medicine
https://www.readbyqxmd.com/read/28263387/adjuvant-chemotherapy-versus-chemoradiotherapy-in-the-management-of-patients-with-surgically-resected-duodenal-adenocarcinoma-a-propensity-score-matched-analysis-of-a-nationwide-clinical-oncology-database
#14
Brett L Ecker, Matthew T McMillan, Jashodeep Datta, Major K Lee, Giorgos C Karakousis, Charles M Vollmer, Jeffrey A Drebin, Douglas L Fraker, Robert E Roses
BACKGROUND: To the authors' knowledge, optimal adjuvant approaches for resected duodenal adenocarcinoma are not well established. Given the significant risk of locoregional disease recurrence, there may be a subset of patients who demonstrate an improvement in overall survival (OS) from the addition of radiotherapy (chemoradiotherapy [CRT]) to an adjuvant chemotherapy regimen. METHODS: Patients with resected, nonmetastatic duodenal adenocarcinoma who received chemotherapy (694 patients) or CRT (550 patients) were identified in the National Cancer Data Base (1998-2012)...
May 15, 2017: Cancer
https://www.readbyqxmd.com/read/28244483/weekly-cisplatin-30-40-mg-m-2-as-radiosensitizer-is-it-high-or-moderate-emetic-agent
#15
A Karpe, V M Patil, A Joshi, V Noronha, S Gupta, A Ramaswamy, A Sahu, V Doshi, T Gupta, S Rath, S Banavali, K Prabhash
PURPOSE: The American Society of Clinical Oncology (ASCO) guideline recommends a high antiemetic prophylaxis for any dose of cisplatin. This hypothesis was tested by us in this analysis of solid tumor patients who received weekly cisplatin as a radiosensitizer in a dose range of 30-40 mg/m2. METHODS: This was a retrospective analysis of 181 solid tumor patients who received weekly cisplatin (in the dose range of 30-40 mg/m2) as a radiosensitizer between July 2015 and August 2015...
July 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28241093/phase-1-2-study-of-immunotherapy-with-dendritic-cells-pulsed-with-autologous-tumor-lysate-in-patients-with-refractory-bone-and-soft-tissue-sarcoma
#16
Shinji Miwa, Hideji Nishida, Yoshikazu Tanzawa, Akihiko Takeuchi, Katsuhiro Hayashi, Norio Yamamoto, Eishiro Mizukoshi, Yasunari Nakamoto, Shuichi Kaneko, Hiroyuki Tsuchiya
BACKGROUND: There are limited options for the curative treatment of refractory bone and soft tissue sarcomas. The purpose of this phase 1/2 study was to assess the immunological and clinical effects of dendritic cells (DCs) pulsed with autologous tumor lysate (TL) in patients with advanced bone and soft tissue sarcomas. METHODS: Thirty-seven patients with metastatic or recurrent sarcomas were enrolled in this study. Peripheral blood mononuclear cells obtained from the patients were suspended in media containing interleukin 4 (IL-4) and granulocyte-macrophage colony-stimulating factor...
February 27, 2017: Cancer
https://www.readbyqxmd.com/read/28241089/adolescent-and-young-adult-oncology-patients-disparities-in-access-to-specialized-cancer-centers
#17
Elysia Alvarez, Theresa Keegan, Emily E Johnston, Robert Haile, Lee Sanders, Olga Saynina, Lisa J Chamberlain
BACKGROUND: Adolescents and young adults (AYAs) ages 15 to 39 years with cancer continue to experience disparate survival outcomes compared with their younger and older counterparts. This may be caused in part by differential access to specialized cancer centers (SCCs), because treatment at SCCs has been associated with improved overall survival. The authors examined social and clinical factors associated with AYA use of SCCs (defined as Children's Oncology Group-designated or National Cancer Institute-designated centers)...
February 27, 2017: Cancer
https://www.readbyqxmd.com/read/28240970/head-and-neck-cancer-survivorship-care-guideline-american-society-of-clinical-oncology-clinical-practice-guideline-endorsement-of-the-american-cancer-society-guideline
#18
Larissa Nekhlyudov, Christina Lacchetti, Nancy B Davis, Thomas Q Garvey, David P Goldstein, J Chris Nunnink, Jose I Ruades Ninfea, Andrew L Salner, Talya Salz, Lillian L Siu
Purpose This guideline provides recommendations on the management of adults after head and neck cancer (HNC) treatment, focusing on surveillance and screening for recurrence or second primary cancers, assessment and management of long-term and late effects, health promotion, care coordination, and practice implications. Methods ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. The American Cancer Society (ACS) HNC Survivorship Care Guideline was reviewed for developmental rigor by methodologists...
February 27, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28237195/validity-and-reliability-of-value-assessment-frameworks-for-new-cancer-drugs
#19
Tanya G K Bentley, Joshua T Cohen, Elena B Elkin, Julie Huynh, Arnab Mukherjea, Thanh H Neville, Matthew Mei, Ronda Copher, Russell Knoth, Ioana Popescu, Jackie Lee, Jenelle M Zambrano, Michael S Broder
BACKGROUND: Several organizations have developed frameworks to systematically assess the value of new drugs. These organizations include the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), the Institute for Clinical and Economic Review (ICER), and the National Comprehensive Cancer Network (NCCN). OBJECTIVES: To understand the extent to which these four tools can facilitate value-based treatment decisions in oncology...
February 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28222220/meaningful-endpoints-for-therapies-approved-for-hematologic-malignancies
#20
B Douglas Smith, Amy E DeZern, Alex W Bastian, Brian G M Durie
BACKGROUND: Overall survival (OS) is considered the gold standard for determining treatment efficacy in oncology trials, but the relation between treatment and OS can be challenging to assess because of long study durations and the impact of subsequent therapies on outcome. Using OS can be particularly difficult for new therapies in hematologic malignancies (HMs). METHODS: This retrospective analysis was conducted to characterize the primary endpoints used to support US Food and Drug Administration (FDA) approvals for new drug or novel HM indications between January 2002 and July 2015...
February 21, 2017: Cancer
keyword
keyword
77718
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"